Ifosfamide in the treatment of relapsed lymphoma

被引：0
|
作者：
Reiser, M [1 ]
Borchmann, P [1 ]
Diehl, V [1 ]
Engert, A [1 ]
机构：
[1] Univ Cologne, Innere Med Klin 1, D-50924 Cologne, Germany
来源：
ONKOLOGIE | 1998年 / 21卷
关键词：
ifosfamide; non-Hodgkin's lymphoma; Hodgkin's lymphoma; salvage therapy; relapse;
D O I：
10.1159/000054967
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Since 1977 ifosfamide has been used for the treatment of relapsed or refractory non-Hodgkin's and Hodgkin's lymphoma. Early phase I/II trials showed efficacy of the drug in patients previously treated with cyclophosphamide. Because of a suggested lack of cross-resistance towards cyclophosphamide, ifosfamide has been used in numerous regimens. Ifosfamide showed clearly efficacy in relapsed lymphoma with response rates between 50 and 70%, Nevertheless, the use of the drug did not show any improvement of long-term survival in this group of patients. Because of its proven efficacy in relapsed lymphoma, ifosfamide is likewise used in newer high-dose chemotherapy protocols followed by autologous stem cell transplantation and in continuous infusion schedules.
引用
下载
收藏
页码：26 / 29
页数：4
相关论文
共 50 条
  • [1] The role of ifosfamide in the treatment of relapsed and refractory lymphoma
    Reiser, M
    Bredenfeld, H
    Engert, A
    Diehl, V
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2001, 66 : 37 - 40
  • [2] Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma
    Dittus, Christopher
    Miller, Jordan A.
    Wehbie, Robert
    Castillo, Jorge J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : E32 - E34
  • [3] Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma
    King, K
    Younes, A
    SEMINARS IN ONCOLOGY, 2000, 27 (01) : 14 - 22
  • [4] TREATMENT OF RELAPSED NON-HODGKINS LYMPHOMA WITH A COMBINATION OF HYDROXYUREA, IFOSFAMIDE, AND ETOPOSIDE
    GASSER, AB
    STEWARD, WP
    WAGSTAFF, J
    SCARFFE, JH
    CROWTHER, D
    CANCER TREATMENT REPORTS, 1985, 69 (02): : 225 - 226
  • [5] TREATMENT OF REFRACTORY AND RELAPSED NON-HODGKINS LYMPHOMA WITH IFOSFAMIDE, METHOTREXATE AND ETOPOSIDE
    SANGSTER, G
    PATTON, WN
    HARRIS, RI
    GRIEVE, RJ
    LEYLAND, MJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 23 (04) : 263 - 265
  • [6] Ifosfamide in the treatment of lymphoma
    Coiffier, B
    SEMINARS IN ONCOLOGY, 1996, 23 (03) : 2 - 7
  • [7] VINORELBINE, IFOSFAMIDE AND PREDNISOLONE AS A SALVAGE REGIMEN IN RELAPSED HODGKIN'S LYMPHOMA
    Abdel-Halim, I.
    El-ashry, M.
    El-sadda, W.
    ANNALS OF ONCOLOGY, 2010, 21 : 354 - 354
  • [8] Docetaxel and Ifosfamide as salvage treatment in relapsed breast cancer
    Schirinzi, M. L.
    Durante, C.
    De Giorgi, D.
    Poti, O.
    Trisolini, M. P.
    De Marzi, A.
    Mancarella, S.
    ANNALS OF ONCOLOGY, 2015, 26 : 23 - 23
  • [9] Treatment of Relapsed Hodgkin Lymphoma
    Ansell, Stephen M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S88 - S90
  • [10] Treatment of Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma with Two Ifosfamide-Based Regimens, IMVP and ICE
    Aurer, I.
    Mitrovic, Z.
    Nemet, D.
    Radman, I.
    Sertic, D.
    Serventi-Seiwerth, R.
    Stern-Padovan, R.
    Santek, F.
    Nola, M.
    Mrsic, M.
    Labar, B.
    JOURNAL OF CHEMOTHERAPY, 2008, 20 (05) : 640 - 644
12345